INTERIM REPORT JANUARY-JUNE 2007

INTERIM REPORT JANUARY-JUNE 2007

• Group revenues from sales of goods and royalties amounted to 665.0 (686.2)
MSEK during the period.

• Growth within the Esthetics product area was 17 percent and revenues amounted
to 537.1 (460.8) MSEK.

• Operating income amounted to 318.2 (212.9) MSEK and the operating margin was
47.9 (34.7) percent.

• Income after tax amounted to 284.0 (151.4) MSEK.

• Earnings per share after full dilution were 2.86 (1.53) SEK.

• RESTYLANE Perlane approved for sales in USA. 
In connection with approval, Q-Med received 29.1 MUSD from Medicis. 


Queries should be addressed to:

Bengt Ågerup, President and CEO
Tel: +46 (0)70-974 9025

Erika Kjellberg Eriksson, Vice President and CFO
Tel: +46 (0)70-974 9020

Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015